On June 3, Praxis Precision Medicines fell 8.94% in after-hours trading, trading at $259.25/share, with trading volume of $212,300. The stock had already declined 15.36% during regular trading before extending losses after hours.

On the news front, the company announced that its Power1 study targeting treatment-resistant focal onset seizures failed to meet the prespecified primary efficacy endpoint, posing a major challenge to the company's core pipeline. For clinical-stage biopharmaceutical companies, failure to achieve a key trial's primary endpoint typically signals significant uncertainty for subsequent development pathways.

Notably, the trial did produce some positive signals — the study achieved a key secondary endpoint of 50% responder rate, with the 30mg dose group demonstrating more significant seizure frequency reduction. Additionally, the drug Vormatrigine showed favorable tolerability, with adverse event discontinuation rates below 10%. However, these secondary results were insufficient to offset market concerns stemming from the primary endpoint failure, as investors reassessed the development prospects for one of the company's lead programs.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)